Table 5 Comparison of TP53 deleterious mutations in this study with ICGC data

Occurrences

Affects 66 distinct donors across 12 cancer projects

Affects 9 distinct donors across 4 cancer projects

Affects 24 distinct donors across 9 cancer projects

Affects 13 distinct donors across 7 cancer projects

Affects 2 distinct donors across 2 cancer projects

Affects 1 distinct donors across 1 cancer project

Occurrences in serous ovarian cancer (ICGC)

6/278 (2.16%)

1/278 (0.36%)

4/278 (1.44%)

1/278 (0.36)

None reported

None reported

Occurrences in serous ovarian cancer (this study)

2/10 (20%)

1/10 (10%)

2/10 (20%)

1/10 (10%)

1/10 (10%)

1/10 (10%)

Other cancers involved

Brain cancer (5/269 (1.86%))

Endometrial cancer (6/766 (0.78%))

Brain cancer (2/269 (0.74%))

Breast cancer (2/117 (1.71%))

Lung cancer (1/111 (0.9%))

Renal cancer (1/407 (0.25%))

Breast cancer (15/766 (1.96%))

Lung cancer (1/246 (0.41%))

Breast cancer (2/117 (1.71%))

Breast cancer (2/766 (0.26%))

Breast cancer (1/943 (0.11%))

Colon cancer 15/261 (5.75%))

Breast cancer (1/178 (0.56%))

Breast cancer (6/766 (0.78%))

Colon cancer (1/261 (0.38%))

Endometrial cancer (2/246 (0.81%))

Colon cancer 2/261 (0.77%))

Liver cancer (3/213 (1.41%))

Esophageal cancer (2/22 (9.09%))

Endometrial cancer (3/246 (1.22%))

Lung cancer (3/178 (1.69%))

Gastric cancer (1/10 (10.00%))

Liver cancer (1/42 (2.38%))

Pancreatic cancer (1/187 (0.53%))

Oral cancer (2/50 (4.00%))

Lung cancer (2/178 (1.12%))

Pancreatic cancer (8/187 (4.28%) and 3/85 (3.53%))

Pancreatic cancer (2/187 (1.07%))

Pediatric brain tumors (1/193 (0.52%))

Rectal cancer (6/109 (5.50%))